

## Statement of Advice:

**abatacept 125mg solution for injection (pre-filled syringe); 125mg solution for injection in pre-filled pen; 250mg powder for concentrate for solution for infusion (Orencia®)** **SMC No 1287/17**

**Bristol-Myers Squibb Pharmaceuticals Limited**

6 October 2017

**ADVICE:** in the absence of a submission from the holder of the marketing authorisation

**abatacept (Orencia®)** is not recommended for use within NHS Scotland.

**Indication under review:** Alone or in combination with methotrexate for the treatment of active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy including methotrexate has been inadequate, and for whom additional systemic therapy for psoriatic skin lesions is not required.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.

### **Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

**Chairman**  
**Scottish Medicines Consortium**